Paolo Durigutto
Overview
Explore the profile of Paolo Durigutto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durigutto P, Grimaldi M, Bozzer S, Raschi E, Meroni P, Tedesco F, et al.
Front Immunol
. 2025 Mar;
16:1520619.
PMID: 40083554
Anti-phospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic vascular occlusion and maternal morbidity. Anti-coagulants remain pivotal drugs for the management of APS, but a significant proportion of...
2.
Mossenta M, Argenziano M, Capolla S, Busato D, Durigutto P, Mangogna A, et al.
Nanomedicine (Lond)
. 2025 Jan;
20(3):255-270.
PMID: 39815170
Background: Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting...
3.
Busato D, Capolla S, Durigutto P, Mossenta M, Bozzer S, Sblattero D, et al.
J Transl Med
. 2023 Nov;
21(1):864.
PMID: 38017492
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest...
4.
Macor P, Durigutto P, Argenziano M, Smith-Jackson K, Capolla S, Di Leonardo V, et al.
Haematologica
. 2022 Sep;
108(7):1861-1872.
PMID: 36172817
β2-glycoprotein I (β2-GPI) is a serum protein widely recognized as the main target of antibodies present in patients with antiphospholipid syndrome (APS). β2-GPI binds to activated endothelial cells, platelets and...
5.
Macor P, Durigutto P, Mangogna A, Bussani R, De Maso L, DErrico S, et al.
Biomedicines
. 2021 Aug;
9(8).
PMID: 34440207
Increased levels of circulating complement activation products have been reported in COVID-19 patients, but only limited information is available on complement involvement at the tissue level. The mechanisms and pathways...
6.
Macor P, Durigutto P, Mangogna A, Bussani R, DErrico S, Zanon M, et al.
medRxiv
. 2021 Jan;
PMID: 33442701
Background: Increased levels of circulating complement activation products have been reported in COVID-19 patients, but only limited information is available on complement involvement at tissue level. The mechanisms and pathways...
7.
Durigutto P, Macor P, Pozzi N, Agostinis C, Bossi F, Meroni P, et al.
J Immunol
. 2020 Aug;
205(5):1385-1392.
PMID: 32759297
β2-Glycoprotein I (β2-GPI) is an abundant plasma glycoprotein with unknown physiological function and is currently recognized as the main target of antiphospholipid Abs responsible for complement activation and vascular thrombosis...
8.
Colombo F, Durigutto P, De Maso L, Biffi S, Belmonte B, Tripodo C, et al.
J Autoimmun
. 2019 Jun;
103:102288.
PMID: 31213399
Despite the advances in the treatment of rheumatoid arthritis (RA) achieved in the last few years, several patients are diagnosed late, do not respond to or have to stop therapy...
9.
Durigutto P, Grossi C, Borghi M, Macor P, Pregnolato F, Raschi E, et al.
Haematologica
. 2018 Nov;
104(4):819-826.
PMID: 30442725
Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 of βglycoproteinI in terms of risk of thrombosis and pregnancy complications in patients with antiphospholipid syndrome....
10.
Meroni P, Borghi M, Grossi C, Chighizola C, Durigutto P, Tedesco F
Nat Rev Rheumatol
. 2018 Jun;
14(7):433-440.
PMID: 29891914
Recurrent thrombosis and miscarriages are the main clinical manifestations of antiphospholipid syndrome (APS). Although most patients display both clinical signs, some patients can have isolated vascular or obstetric variants. Emerging...